COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02811185
Recruitment Status : Completed
First Posted : June 23, 2016
Last Update Posted : May 4, 2017
Sylvia Fedoruk Canadian Centre for Nuclear Innovation
Saskatoon Health Region
Information provided by (Responsible Party):
Paul Babyn, University of Saskatchewan

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : January 2017
Actual Study Completion Date : January 30, 2017
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 26, 2019
May 21, 2019